1. Senology Newsletter Page 1 of 3
Senology.org - Newsletter
International Senologic and Oncologic Scientific Community (ISOSC)
"Connecting specialists worldwide"
Editor-in-Chief: Gian Paolo Andreoletti, MD
Subscribe Unsubscribe Contact Back Issues
Connecting Specialists Worldwide
SENOLOGY GROUP on LiINKEDIN now has more than 1000 MEMBERS! JOIN US!
Join us on LinkedIn, ResearchGate, Doctorsbook, Twitter, Facebook, Google Groups, YouTube, SlideShare,
Flickr, and share informations and opinions. Check out Senology.org Newspaper and follow our RSS feeds for
real-time updates
Literature Selection
Menegaux F et al.: "Night work and breast cancer: A population-based case-control study in France
(the CECILE study)", Int J Cancer. 2012 Jun 12 [Epub ahead of print]
Chlebowski RT et al.: "Diabetes, Metformin, and Breast Cancer in Postmenopausal Women", J Clin
Oncol. 2012 Jun 11. [Epub ahead of print]
Hoff SR et al.: "Breast Cancer: Missed Interval and Screening-detected Cancer at Full-Field Digital
Mammography and Screen-Film Mammography-- Results from a Retrospective Review", Radiology.
2012 Jun 14. [Epub ahead of print]
Huober J et al.: "Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer
Study Group (IBCSG) trials", Ann Oncol. 2012 Jun 14. [Epub ahead of print]
De Cicco C et al.: "Is [(18)F] fluorodeoxyglucose uptake by the primary tumor a prognostic factor in
breast cancer?", Breast. 2012 Jun 13. [Epub ahead of print]
Onitilo AA et al.: "Clustering of venous thrombosis events at the start of tamoxifen therapy in breast
cancer: A population-based experience", Thromb Res. 2012 Jul;130(1):27-31
Kubo M et al.: "Short-term and Low-dose Prednisolone Administration Reduces Aromatase Inhibitor-
induced Arthralgia in Patients with Breast Cancer", Anticancer Res. 2012 Jun;32(6):2331-6
Retsky M et al.: "NSAID analgesic ketorolac used perioperatively may suppress early breast cancer
relapse: particular relevance to triple negative subgroup", Breast Cancer Res Treat. 2012 May 24.
[Epub ahead of print]
van Walsum GA et al.: "Resection of liver metastases in patients with breast cancer: Survival and
prognostic factors", Eur J Surg Oncol. 2012 Jun 6. [Epub ahead of print]
Arvold ND et al.: "Pathologic characteristics of second breast cancers after breast conservation for
ductal carcinoma in situ", Cancer. 2012 Jun 6 [Epub ahead of print]
file://C:Documents and SettingsutenteDesktopNewsl_Jul2012.htm 03/07/2012
2. Senology Newsletter Page 2 of 3
Comment
"Importance of circulating tumour cells in patients with non-metastatic breast cancer", Anthony Lucci,
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
"The results of our study showed that presence of one or more circulating tumor cells (CTCs) in patients with
stage I-III breast cancer carried a four times greater chance of a recurrence or death. Increasing numbers of
CTCs carried even higher hazard ratios, as patients with three or more CTCs had an 11.5 times higher risk of
dying from their breast cancer. CTCs also did not correlate with axillary lymph node status or primary tumor
characteristics, suggesting that CTC measurement might provide complementary information to standard
primary tumor analysis and lymph node staging. The caveat to this study is we now have a prognostic marker
that we don’t really know how to best use in clinical decision–making. Larger studies will be needed to identify
subgroups wherein information on CTCs can help guide treatment decisions. An example would be the group
of estrogen receptor-positive, lymph node-negative patients, where oftentimes the benefit for chemotherapy is
not completely clear. Future studies will no doubt shed light on when the information from CTCs can be used
in the clinic to optimize therapy, but for now we believe the test is still best utilized in clinical studies where we
can gather such information"
(Commentary on: Lucci A et al.: "Circulating tumour cells in non-metastatic breast cancer: a
prospective study", Lancet Oncol. 2012 Jun 1. [Epub ahead of print])
Calendar of Events
IBUS Update in Breast Imaging, 19 - 22 September 2012, Ferrara, Italy
17th World Congress on Breast Diseases of the Senologic International Society, -SIS, October 10-13,
2012, Salvador, Bahia, Brazil
Breast Cancer in Young Women Conference, 8-10 November 8-10, 2012, Dublin, Ireland
IBUS - International Breast Ultrasound Course, 13 - 15 November 2012, Tel Aviv, Israel
8th Meet the Professor. Advanced International Breast Cancer Conference (AIBCC), November 15-17,
2012, Padova , Italy
Literature Selection
Wu S et al.: "Fish Consumption and Colorectal Cancer Risk in Humans: A Systematic Review and
Meta-analysis", Am J Med. 2012 Jun;125(6):551-559.e5
Sanoff HK et al.: "Effect of Adjuvant Chemotherapy on Survival of Patients With Stage III Colon
Cancer Diagnosed After Age 75 Years", J Clin Oncol. 2012 Jun 4. [Epub ahead of print]
Pearce MS et al.: "Radiation exposure from CT scans in childhood and subsequent risk of leukaemia
and brain tumours: a retrospective cohort study", Lancet. 2012 Jun 6. [Epub ahead of print]
Shafique et al.: "Tea Consumption and the Risk of Overall and Grade Specific Prostate Cancer: A
Large Prospective Cohort Study of Scottish Men", Nutr Cancer. 2012 Jun 14. [Epub ahead of print]
Sun M et al.: "Is a Treatment Delay in Radical Prostatectomy Safe in Individuals with Low-Risk
Prostate Cancer?", J Sex Med. 2012 Jun 6 [Epub ahead of print]
Maule M et al.: "Age at puberty and risk of testicular cancer: a meta-analysis", Int J Androl. 2012 Jun
19 [Epub ahead of print]
Fragments of History
Pierre Curie (Paris, 1859–1906) and Marie Sklodowska Curie (Warsaw, 1867–1934) discovered the
radioactive element radium in 1898
Discussion
""Preoperative diagnosis with gene-expression test can distinguish benign from malignant thyroid
nodules, reducing need for surgery " - Share your opinion on LinkedIn®
Literature Selection
file://C:Documents and SettingsutenteDesktopNewsl_Jul2012.htm 03/07/2012
3. Senology Newsletter Page 3 of 3
Lidegaard O et al.: "Thrombotic stroke and myocardial infarction with hormonal contraception", N
Engl J Med. 2012 Jun 14;366(24):2257-66
Senology.org collaborates with TalkAboutHealth.com - "Cancer questions, answers, and support". Follow the
Expert Q&A Workshops and join the conversation.
TalkAboutHealth Q&A of the month
"What is the significance of BRAF mutations in colorectal cancer?"
"Mutations in the BRAF gene have recently become the subject of significant attention. At this point, it
is clear that having a BRAF mutation means that a colon cancer has a worse prognosis. However,
there is no current suggestion that these patients should be treated differently and the anti-EGFR
antibodies (cetuximab and panitumumab) can still be considered. Even though these drugs do not
seem to work in patients with a KRAS mutation, most studies suggest that they can still work in
patients with BRAF mutations but perhaps not as well. Unfortunately, the specific drug that blocks
BRAF that is successful in melanoma (a cancer that has 50% BRAF mutations) did not demonstrate
much activity in BRAF mutant colon cancer"
(Answer by Zev Wainberg, UCLA/Santa Monica Cancer Center, CA, USA)
.
Happy Holidays!
Unsubscribe
www.senology.org
file://C:Documents and SettingsutenteDesktopNewsl_Jul2012.htm 03/07/2012